Paving the way to a bioresorbable technology: Development of the absorb BRS program.

about

Translation in cardiovascular stents and occluders: From biostable to fully degradable.Lessons Learned Regarding Handling and Deployment of the Absorb Bioresorbable Vascular Scaffold in Infrapopliteal Arteries.

P2860

Q52724991-B95980BD-D3E0-4DE5-A153-7424DDFEF540 Q53395034-EF094FB4-F439-422C-9929-F17A37AD6510

P2860

Paving the way to a bioresorbable technology: Development of the absorb BRS program.

Item

http://www.wikidata.org/entity/Q38995000

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Paving the way to a bioresorbable technology: Development of the absorb BRS program.

@en

type

Item

label

Paving the way to a bioresorbable technology: Development of the absorb BRS program.

@en

prefLabel

Paving the way to a bioresorbable technology: Development of the absorb BRS program.

@en

P1476

Paving the way to a bioresorbable technology: Development of the absorb BRS program.

@en

P2093

Julia C Fox

http://www.w3.org/2001/XMLSchema#string

Laura E Leigh Perkins

http://www.w3.org/2001/XMLSchema#string

Mary Beth Kossuth

http://www.w3.org/2001/XMLSchema#string

Richard J Rapoza

http://www.w3.org/2001/XMLSchema#string

P2860

Absorbable magnesium-based stent: physiological factors to consider for in vitro degradation assessments

Current status of bioresorbable scaffolds in the treatment of coronary artery disease

A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits.

Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation.

Compensatory enlargement of human atherosclerotic coronary arteries.

A simplified in vivo approach for evaluating the bioabsorbable behavior of candidate stent materials.

Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.

Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months.

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.

Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CCD.26811

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27797462

http://www.w3.org/2001/XMLSchema#string

Paving the way to a bioresorbable technology: Development of the absorb BRS program.

about

P2860

P2860

Paving the way to a bioresorbable technology: Development of the absorb BRS program.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698